In 2010, CLC bio was notable as the first commercial platform for bioinformatics analysis that utilized a graphical user interface for building, managing, and deploying analysis workflows as well as command-line tools, a SOAP and REST API, and later, the ability to run containerized tools. CLC bio developed some of their own open source algorithms, as well as their own SIMD-accelerated implementations of several existing popular applications. Software ĬLC bio's main activities were in software development for desktop ( Mac OS X, Windows, and Linux), enterprise, and cloud software for analysis of biological data. ĬLC bio was acquired by QIAGEN in 2013 and merged into its bioinformatics research and development division with several other purchased platforms in 2014. By 2012, it had additional offices in Cambridge, Massachusetts, Tokyo, Taipei and Delhi, with staff largely from research backgrounds (30% having a PhD) and had built a userbase of around 250,000 users in both academic institutions and biotechnology companies. Its product's development was also partly funded by collaborating with researchers on grant-funded projects. CLC bio was a bioinformatics software company that developed a software suite subsequently purchased by QIAGEN.ĬLC bio started commercial activities on Januheadquartered in Aarhus, Denmark.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |